Beta-Blockers in Cardiovascular Disease

Left Ventricular Systolic Dysfunction

The American College of Cardiology recommends that beta-blockers should be used in all patients with left ventricular systolic dysfunction (EF ≤40%) with heart failure or prior myocardial infarction, unless contraindicated, using only carvedilol, metoprolol succinate, or bisoprolol, which have been shown to reduce mortality 1, 2, 3.
Beta-blockers counteract the harmful effects of chronic sympathetic activation in heart failure by reducing myocardial oxygen demand, preventing arrhythmias, and allowing reverse remodeling of the failing ventricle 4, 5.
Long-term treatment with beta-blockers lessens symptoms, improves clinical status, enhances overall well-being, and reduces the risk of death and combined risk of death or hospitalization in patients with reduced left ventricular ejection fraction (LVEF) 4.
The favorable effects of beta-blockers extend to patients with or without coronary artery disease, with or without diabetes mellitus, and include women and Black patients 4.

The American College of Cardiology recommends that beta-blocker therapy should be started and continued for 3 years in all patients with normal left ventricular function who have had myocardial infarction or acute coronary syndrome, unless contraindicated 1, 2, 3.
It is reasonable to continue beta-blockers beyond 3 years as chronic therapy in all patients with normal left ventricular function who have had myocardial infarction or acute coronary syndrome 1, 2.
Beta-blockers reduce mortality in post-myocardial infarction patients through multiple mechanisms: decreasing myocardial oxygen consumption, preventing reinfarction, and markedly reducing sudden cardiac death 5.

For atrial fibrillation with left ventricular ejection fraction (LVEF) >40%, the European Society of Cardiology recommends beta-blockers, diltiazem, verapamil, or digoxin as first-choice drugs to control heart rate and reduce symptoms 6, 7.
For atrial fibrillation with LVEF ≤40%, the European Society of Cardiology recommends beta-blockers and/or digoxin, while diltiazem and verapamil should be avoided due to negative inotropic effects 6, 7.
Beta-blockers are the preferred agents for achieving rate control in atrial fibrillation unless otherwise contraindicated, due to their favorable effect on morbidity and mortality in patients with systolic heart failure 8.
For acute rate control, beta-blockers and diltiazem/verapamil are preferred over digoxin because of their rapid onset of action and effectiveness at high sympathetic tone 9.
Digoxin is effective following oral administration to control heart rate at rest and is particularly indicated for patients with heart failure, left ventricular dysfunction, or sedentary individuals 10.

Beta-blockers should be initiated as soon as left ventricular dysfunction is diagnosed, even when symptoms are mild or have responded to other therapies, to reduce risk of disease progression and sudden death 4.
Patients need not be taking high doses of ACE inhibitors before starting beta-blockers; in fact, adding a beta-blocker produces greater improvement than increasing ACE inhibitor dose 4.
Start with low doses (e.g., carvedilol 3.125 mg twice daily, metoprolol succinate 12.5-25 mg daily, bisoprolol 1.25 mg daily) and titrate gradually over weeks to months 4.

The American College of Cardiology and American Heart Association recommend guideline-directed medical therapy (GDMT) with beta-blockers (bisoprolol, carvedilol, or metoprolol succinate) as a Class I recommendation specifically for patients with current or prior LVEF ≤40% to reduce morbidity and mortality 11, 12, 13
The 2022 AHA/ACC/HFSA guidelines explicitly state beta-blockers should be used in patients with LVEF ≤40% in Stage B heart failure (pre-heart failure) and symptomatic heart failure 11

The American College of Cardiology recommends beta-blockers should be started and continued for 3 years in all patients with normal LV function who have had MI or acute coronary syndrome, regardless of EF in the 41-50% range 14
The American College of Cardiology suggests it is reasonable to continue beta-blockers beyond 3 years as chronic therapy in patients with normal LV function who have had MI or acute coronary syndrome 14
The American Heart Association and American College of Cardiology recommend uptitration of GDMT to maximally tolerated target dose in patients with heart failure (any EF) and hypertension, which may include beta-blockers if already prescribed for other indications 11

The American College of Cardiology and American Heart Association state that the mortality benefit of beta-blockers is specific to HFrEF (EF ≤40%) 11, 12
The American College of Cardiology and American Heart Association recommend only carvedilol, metoprolol succinate, or bisoprolol for HFrEF due to their proven mortality benefit 11, 12, 13
The American College of Cardiology and American Heart Association suggest that Stage B patients with LVEF ≤40% should receive beta-blockers even without symptoms 11

The American College of Cardiology and American Heart Association recommend determining the primary indication for beta-blocker use, with EF ≤40% being a Class I indication for beta-blocker therapy 11, 12
The American College of Cardiology recommends assessing for alternative indications, such as recent MI or ACS, atrial fibrillation requiring rate control, or hypertension requiring additional agent, when EF is 41-50% 11, 14

The European Society of Cardiology recommends that beta-blockers should be continued indefinitely in all patients with reduced systolic left ventricular function (LVEF ≤40%), regardless of time since myocardial infarction 15
The American Heart Association/American College of Cardiology Foundation guidelines suggest using only evidence-based agents: carvedilol, metoprolol succinate, or bisoprolol, which provide a 23% reduction in odds of death in long-term trials and reduce reinfarction by 20-25% 16

The American Heart Association recommends continuing beta-blockers indefinitely in patients with heart failure or hypertension, as they are effective antihypertensive agents and may be reasonable beyond 3 years post-myocardial infarction in patients requiring blood pressure control 17
Beta-blockers remain effective antianginal agents by decreasing myocardial oxygen demand through reducing heart rate, blood pressure, and contractility, and improve coronary perfusion by prolonging diastole 16, 18

The European Society of Cardiology notes that no study has properly addressed beta-blocker duration to date, and no recommendation regarding duration can be made, with a multicentre registry of 7,057 patients showing mortality reduction at 2.1 years follow-up, but no dose-response relationship was identified 15
A study of 19,843 patients found beta-blocker benefit differed significantly between patients with and without recent myocardial infarction (HR for death 0.85 vs. 1.02; P=0.007) 15